Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study

BACKGROUND: Nivolumab improved overall survival (OS) and objective response rate (ORR) versus everolimus in previously treated patients with advanced renal cell carcinoma in the phase III CheckMate 025 study (minimum follow-up: 14 months). We report efficacy and safety in the global and Japanese pop...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yoshihiko, Fukasawa, Satoshi, Shinohara, Nobuo, Kitamura, Hiroshi, Oya, Mototsugu, Eto, Masatoshi, Tanabe, Kazunari, Kimura, Go, Yonese, Junji, Yao, Masahiro, Motzer, Robert J., Uemura, Hirotsugu, McHenry, M. Brent, Berghorn, Elmer, Ozono, Seiichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896687/
https://www.ncbi.nlm.nih.gov/pubmed/28419248
http://dx.doi.org/10.1093/jjco/hyx049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896687/
https://www.ncbi.nlm.nih.gov/pubmed/28419248
http://dx.doi.org/10.1093/jjco/hyx049

Ejemplares similares